Journal of Clinical Oncology

Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story

R Rik J. Verheijden (Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...) J Jolien S. de Groot (Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...) B Babs O. Fabriek (Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...) M Miki N. Hew (Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...) A Anne M. May K Karijn P.M. Suijkerbuijk (Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...)
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 43, Issue 5
Published February 10, 2025
Pages 616-619
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (6)

R

Rik J. Verheijden

Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...

J

Jolien S. de Groot

Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...

B

Babs O. Fabriek

Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...

M

Miki N. Hew

Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...

A

Anne M. May

K

Karijn P.M. Suijkerbuijk

Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health...

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001